课题基金 / 基金详情

Novel Effectors of GRB2 in Human Glial Tumors

Novel Effectors of GRB2 in Human Glial Tumors
GRB2 在人类胶质瘤中的新效应子
批准号:
7577554
负责人:
ALBERT J. WONG
金额:
$31.61万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1996
资助国家:
美国
项目状态:
已结题
起止时间:
1996-04-15 至 2010-02-28

项目摘要

项目成果

ALBERT J. WONG的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Gab1 is a docking protein that is downstream of multiple receptor tyrosine kinases (RTKs). Our goals are to further understand the role of Gab1 in EGF receptor and reactive oxygen species (ROS) signaling and how it participates in the process of gliomagenesis. We have shown that Gab1 can be a substrate for the SHP-2 tyrosine phosphatase and this interaction is essential for cell growth and transformation in NIH3T3 cells. In contrast, under oxidative stress we find that the Gab1/SHP-2 complex promotes cell death and is correlated with JNK activation. For the first time, we have observed that Gab1 is overexpressed in high grade astrocytoma tumors in comparison with normal glia, suggesting a role for Gab1 in gliomagenesis. It also presents two different patterns of localization, one diffuse and the other an unusual vesicular staining at the periphery which increases in frequency with tumor grade. In Specific Aim #1, we will study the role of Gab1 in cell growth and transformation by: 1) analyzing the sites in Gab1 dephosphorylated by SHP-2; 2) using this information to identify the pathways downstream of the Gab1/SHP2 interaction responsible for cell growth and/or transformation. Specific Aim #2 will focus on its role in ROS stimulation by :1) studying the localization of Gab1/SHP2 interaction after oxidative stress via FRET and cell fractionation; 2) the phosphorylation sites of Gab1 after H2O2 addition as revealed by MS-MALDI; and 3) how JNK is specifically activated by the Gab1/SHP-2 interaction. In Specific Aim #3, we will examine the role of Gab1 in astrocytomas by studying: 1) if knock down of Gab1 expression in grade III and grade IV cell lines impairs tumorigenicity; 2) if the presence of Gab1 correlates with grade IV tumors arising from the secondary pathway; and 3) what is the nature of the vesicle-like structure where Gab1 is localized. This work will apply state of the art tools that have not been extensively used in cancer cells and may reveal new aspects of how cellular localization correlates with signaling and unique properties of signaling molecules in tumors.
期刊论文(19)
专著(0)
科研奖励(0)
会议论文
Pineal parenchymal tumor of intermediate differentiation: clinicopathological report and analysis of epidermal growth factor receptor variant III expression.
松果体实质肿瘤中分化:临床病理报告和表皮生长因子受体变异体III表达分析。
DOI: 10.1227/01.neu.0000367726.49003.f1
发表时间: 2010
期刊: Neurosurgery
影响因子: 4.8
作者: [Li,Gordon, Mitra,Siddhartha, Karamchandani,Jason, Edwards,MichaelSB, Wong,AlbertJ]
通讯作者: Wong,AlbertJ
DOI: --
发表时间: 2003
期刊: Cancer research
影响因子: 11.2
作者: [Hiromasa Tsuiki;M. Tnani;I. Okamoto;L. Kenyon;D. Emlet;Marina Holgado-Madruga;I. Lanham;Christopher J Jo]
通讯作者: Hiromasa Tsuiki;M. Tnani;I. Okamoto;L. Kenyon;D. Emlet;Marina Holgado-Madruga;I. Lanham;Christopher J Jo
DOI: 10.1083/jcb.200108159
发表时间: 2001-11-26
期刊: The Journal of cell biology
影响因子: --
作者: [Okamoto I, Kawano Y, Murakami D, Sasayama T, Araki N, Miki T, Wong AJ, Saya H]
通讯作者: Saya H
DOI: 10.1186/1472-6750-10-72
发表时间: 2010-10-07
期刊: BMC biotechnology
影响因子: 3.5
作者: [Gupta P, Han SY, Holgado-Madruga M, Mitra SS, Li G, Nitta RT, Wong AJ]
通讯作者: Wong AJ
A Novel Paradigm for the Development of a Peptide Vaccine to Treat KRAS Mutant Cancers
  • 批准号:
    10438897
  • 项目类别:
  • 资助金额:
    $18.06万
  • 财政年份:
    2021
  • 负责人:
    ALBERT J. WONG
  • 依托单位:
A Novel Paradigm for the Development of a Peptide Vaccine to Treat KRAS Mutant Cancers
  • 批准号:
    10290826
  • 项目类别:
  • 资助金额:
    $22.12万
  • 财政年份:
    2021
  • 负责人:
    ALBERT J. WONG
  • 依托单位:
Using Insights from EGFRvIII to Improve EGFR Directed Therapy in Human Gliomas
  • 批准号:
    7184032
  • 项目类别:
  • 资助金额:
    $30.09万
  • 财政年份:
    2007
  • 负责人:
    ALBERT J. WONG
  • 依托单位:
Using Insights from EGFRvIII to Improve EGFR Directed Therapy in Human Gliomas
  • 批准号:
    7629773
  • 项目类别:
  • 资助金额:
    $30.1万
  • 财政年份:
    2007
  • 负责人:
    ALBERT J. WONG
  • 依托单位:
海外基金